<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Medical Device Manufacturers Association</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Compliance still important under new Department of Justice</title>
      <description>
        <![CDATA[The U.S. Department of Justice may have dismantled its civil division, but that doesn’t mean companies in the life sciences can let their guard down.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719549</guid>
      <pubDate>Fri, 02 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719549-compliance-still-important-under-new-department-of-justice</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/regulatory-washington-us-flag.webp?t=1588689518" type="image/png" medium="image" fileSize="594023">
        <media:title type="plain">U.S. flag on columned building</media:title>
      </media:content>
    </item>
    <item>
      <title>CMS vows to put more emphasis on MA plans’ prior authorization</title>
      <description>
        <![CDATA[Physicians aren’t the only ones who see prior authorization (PA) practices as a significant problem, but John Brooks, deputy administrator at CMS, told a med tech audience that a renewed focus on Medicare Advantage plans’ use of PA will not yield tangible results overnight.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719548</guid>
      <pubDate>Fri, 02 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719548-cms-vows-to-put-more-emphasis-on-ma-plans-prior-authorization</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-logo-and-website.webp?t=1689968782" type="image/jpeg" medium="image" fileSize="122536">
        <media:title type="plain">CMS logo and website</media:title>
      </media:content>
    </item>
    <item>
      <title>Klobuchar reiterates opposition to Trump tariffs</title>
      <description>
        <![CDATA[  Sen. Amy Klobuchar (D-Minn.) spoke to an industry meeting in Washington and expressed concerns about the situation at the U.S. FDA, but she also blasted the tariffs put in place by the Trump administration as lacking the proper statutory authority.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719538</guid>
      <pubDate>Thu, 01 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719538-klobuchar-reiterates-opposition-to-trump-tariffs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/regulatory-washington-capital.webp?t=1588689711" type="image/png" medium="image" fileSize="560021">
        <media:title type="plain">U.S. Capitol building, Washington D.C.</media:title>
      </media:content>
    </item>
    <item>
      <title>Synchron links brain implant device to Apple Vision Pro</title>
      <description>
        <![CDATA[Neurotech startup Synchron Inc. connected its brain implant to Apple’s Vision Pro headset, enabling patients with limited physical mobility to control the device using only their thoughts. Synchron is building an endovascular brain-computer interface designed to help patients with paralysis operate technology like smartphones and computers with their minds.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710966</guid>
      <pubDate>Fri, 02 Aug 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710966-synchron-links-brain-implant-device-to-apple-vision-pro</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Synchron-Inc-Stentrode-brain-implant-May-2022close-up.png.webp?t=1722632256" type="image/jpeg" medium="image" fileSize="237776">
        <media:title type="plain">Synchron Inc Stentrode brain implant </media:title>
        <media:description type="plain">Synchron Inc Stentrode brain implant. Credit: Synchron</media:description>
      </media:content>
    </item>
    <item>
      <title>Ykrita enhances IP for its artificial ectopic liver device</title>
      <description>
        <![CDATA[In just its second PCT filing, Ykrita Lifesciences Private Ltd. (YLS) continues to assemble intellectual property for its development of an extracorporeal bioengineered dual-cell liver regeneration (EBDLR) system which serves as a lightweight, portable, ectopic liver device to aid in the rejuvenation of the body’s own liver and treat acute liver failure without the need for surgery.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709480</guid>
      <pubDate>Wed, 19 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709480-ykrita-enhances-ip-for-its-artificial-ectopic-liver-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/ykrita-ectopic-liver-device-19june24.webp?t=1718829713" type="image/jpeg" medium="image" fileSize="123455">
        <media:title type="plain">Ykrita ectopic liver device</media:title>
        <media:description type="plain">WO2024105681-A1, “Extracorporeal bioengineered dual-cell liver regeneration system (EBDLR) and bio purifier therefor.”Assignee: Ykrita Lifesciences Private Ltd.Inventors: Datey, Akshay; Gopalan, Jagadeesh; Gopasetty, MaheshIPC Codes: A61M 1/36; A61K 38/00; A01N 1/02Publication Date: May 23, 2024Earliest Priority Details: IN202241066541, Nov. 19, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>UK considering mutual recognition for FDA device reviews</title>
      <description>
        <![CDATA[Reliance may be the regulatory buzzword of the moment, but mutual recognition agreements between regulators are much more near and dear to the hearts of device makers. Richard Phillips, director of strategy for Association of British Health Tech Industries Ltd., told an audience of device makers that the U.K. is considering recognition of devices approved and cleared by the FDA, although Phillips said such recognition for 510(k) devices might be less than a simple exercise.]]>
      </description>
      <guid>http://www.bioworld.com/articles/707466</guid>
      <pubDate>Fri, 19 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/707466-uk-considering-mutual-recognition-for-fda-device-reviews</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Gears-with-words.webp?t=1701979068" type="image/jpeg" medium="image" fileSize="381498">
        <media:title type="plain">Gears with regulatory words</media:title>
      </media:content>
    </item>
    <item>
      <title>MDMA’s Leahey: ACA supporters saw device tax as ‘a spreadsheet exercise’</title>
      <description>
        <![CDATA[The 2.3% tax on medical devices is a thing of the past. Now, Mark Leahey, president and CEO of the Medical Device Manufacturers Association (MDMA), has revealed to <em>BioWorld</em> that the supporters of the Affordable Care Act (ACA) saw the tax as little more than &ldquo;a spreadsheet exercise&rdquo; in financing the more costly elements of the legislation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432626</guid>
      <pubDate>Fri, 24 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432626-mdmas-leahey-aca-supporters-saw-device-tax-as-a-spreadsheet-exercise</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-capital-washington-congress-government.webp?t=1588689267" type="image/png" medium="image" fileSize="2212023">
        <media:title type="plain">U.S. Capitol building</media:title>
      </media:content>
    </item>
  </channel>
</rss>
